Annual general meeting

Culp Announces 2023 Annual Meeting Date

Retrieved on: 
Thursday, August 3, 2023
Home Goods, Other Manufacturing, Textiles, Specialty, Consumer, Other Consumer, Manufacturing, Retail, Annual general meeting, NYSE, 3D printing

Culp, Inc. (NYSE: CULP) today announced that it will hold its 2023 Annual Meeting of Shareholders on Wednesday, September 27, 2023, at 12:00 p.m. Eastern Time.

Key Points: 
  • Culp, Inc. (NYSE: CULP) today announced that it will hold its 2023 Annual Meeting of Shareholders on Wednesday, September 27, 2023, at 12:00 p.m. Eastern Time.
  • Additional information will be provided in the company’s proxy statement to be filed with the SEC and sent to shareholders.
  • Culp, Inc. is one of the world’s largest marketers of mattress fabrics for bedding and upholstery fabrics for residential and commercial furniture.
  • Culp has manufacturing and sourcing capabilities located in the United States, Canada, China, Haiti, Turkey, and Vietnam.

EQS-News: BAUER Aktiengesellschaft: Executive Board member Peter Hingott reports on the 2022 financial year at the General Meeting

Retrieved on: 
Thursday, August 3, 2023
Equipment, Executive, Frankfurt Stock Exchange, Mass meeting, Annual general meeting, Article, RTÉ Executive Board, Acquisition, Articles of association, SD, Management

Schrobenhausen, Germany – During today's General Meeting of BAUER Aktiengesellschaft, the shareholders approved the proposed resolutions for agenda items 3 to 6 by a large majority.

Key Points: 
  • Schrobenhausen, Germany – During today's General Meeting of BAUER Aktiengesellschaft, the shareholders approved the proposed resolutions for agenda items 3 to 6 by a large majority.
  • With the exception of one departing member, the current members of the Executive Board were discharged by a large majority.
  • Among other resolutions, the General Meeting also approved a change to the Articles of Association which authorizes the Executive Board to also convene a virtual General Meeting in the future.
  • The voting results and the presentation by the Executive Board and other documents related to the General Meeting can be found online at www.bauer.de in the Investor Relations area.

Check Point Software Technologies Ltd. Shareholders Approve All 2023 Annual General Meeting Proposals

Retrieved on: 
Thursday, August 3, 2023
Point, SAN, Annual general meeting, Security (finance), Auction, Management

SAN CARLOS, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Check Point® Software Technologies Ltd. (NASDAQ: CHKP) today announced that shareholders approved all five proposals presented at the 2023 Annual General Meeting.

Key Points: 
  • SAN CARLOS, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Check Point® Software Technologies Ltd. (NASDAQ: CHKP) today announced that shareholders approved all five proposals presented at the 2023 Annual General Meeting.
  • Approximately 93.6 million shares, representing approximately 80% of the shares outstanding as of the record date, were voted at the meeting.
  • Check Point would like to thank shareholders for the support and confidence they have in the company and its employees.
  • For more information on the agenda items, please see the company’s proxy statement for the annual general meeting of shareholders:

Replimune Reports Fiscal First Quarter 2024 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, August 3, 2023
Bevacizumab, Radiation, CRC, Skin, Roche, Clinical trial, Merkel-cell carcinoma, SCCHN, Data collection, Uveal melanoma, RP3, Incyte, SOC, Cisplatin, RP1, ASCO, ORR, CSCC, American Society of Clinical Oncology, Cytokine release syndrome, Patient, Standard of care, Melanoma, Carcinoma, CPS, Annual general meeting, Liver, Nivolumab, ATC, RP2, Kinetics, BLA, PD-L1, Society, Safety, Fatigue, Pharmaceutical industry, Vaccine, Medical imaging, Nursing

“It was a productive quarter with positive updates for RP1 in anti-PD1 failed melanoma and RP2 in uveal melanoma presented at ASCO.

Key Points: 
  • “It was a productive quarter with positive updates for RP1 in anti-PD1 failed melanoma and RP2 in uveal melanoma presented at ASCO.
  • S,G&A Expenses: Selling, general and administrative expenses were $15.2 million for the first quarter ended June 30, 2023, as compared to $11.4 million for the first quarter ended June 30, 2022.
  • Selling, general and administrative expenses included $5.5 million in stock-based compensation expenses for the first quarter ended June 30, 2023.
  • Net Loss: Net loss was $49.6 million for the first quarter ended June 30, 2023, as compared to a net loss of $42.3 million for the first quarter ended June 30, 2022.

Dyne Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights

Retrieved on: 
Thursday, August 3, 2023
European Medicines Agency, DYN, Dystrophin, Central nervous system, Duchenne muscular dystrophy, Therapy, Gene, DM1, Pharmacokinetics, G&A, Cardiac muscle, Brain, Facial muscles, Biomarker, CNS, EMA, Neuromuscular disease, DMD, Patient, Enrollment, FORCE, Annual general meeting, Cell, MAD, R, Research, Safety, Society, Pharmaceutical industry, Medical imaging, Dyne

WALTHAM, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today reported financial results for the second quarter of 2023 and business highlights.

Key Points: 
  • (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today reported financial results for the second quarter of 2023 and business highlights.
  • Research and development (R&D) expenses: R&D expenses were $59.1 million for the quarter ended June 30, 2023, compared to $46.7 million for the quarter ended June 30, 2022.
  • General and administrative (G&A) expenses: G&A expenses were $7.6 million for the quarter ended June 30, 2023, compared to $6.1 million for the quarter ended June 30, 2022.
  • Net loss: Net loss for the quarter ended June 30, 2023 was $64.9 million, or $1.08 per basic and diluted share.

Agios Reports Business Highlights and Second Quarter 2023 Financial Results

Retrieved on: 
Thursday, August 3, 2023
Glioma, Workforce, PK, Business development, The New England Journal of Medicine, Thalassemia, SG, Anti-transglutaminase antibodies, Sickle cell disease, Small RNA, AGIO, MDS, ASCO, Public expenditure, Agios, American Society of Clinical Oncology, Patient, Administration, Annual general meeting, RISE, IDH, Research and development, R, Agios Pharmaceuticals, Rare, Research, FDA, Polycythemia, Security, Society, Myelodysplastic syndrome, Pharmaceutical industry, Cryptocurrency, Fine chemical, Alnylam Pharmaceuticals

Launch: Generated $6.7 million in U.S. net revenue for the second quarter of 2023, a 20 percent increase over the first quarter of 2023.

Key Points: 
  • Launch: Generated $6.7 million in U.S. net revenue for the second quarter of 2023, a 20 percent increase over the first quarter of 2023.
  • Research and Development (R&D) Expenses: R&D expenses were $68.9 million for the second quarter of 2023 compared to $74.5 million for the second quarter of 2022.
  • Net Loss: Net loss was $83.8 million for the second quarter of 2023 compared to $91.8 million for the second quarter of 2022.
  • ET to discuss second quarter 2023 financial results and recent business activities.

Voyager Therapeutics Reports Second Quarter 2023 Financial and Operating Results

Retrieved on: 
Thursday, August 3, 2023
GLP, HD, GBA1, Gene, Ataxia, HTT, Conference call, Disease, Telephone, Neurocrine Biosciences, Neurocrine, TRACER, G&A, Huntington's disease, Research, Brain, CNS, Small RNA, SOD1, Novartis, Prion, FXN, MSH3, Annual general meeting, Cell, Toxicology, Mouse, Sirna Therapeutics, Growth, FDA, Therapy, ALS, IND, Neurology, Conference, Society, Sangamo Therapeutics, VY, D, Vaccine, Pharmaceutical industry, Fine chemical, Cryptocurrency, Voyager

CAMBRIDGE, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today reported second quarter 2023 financial and operating results.

Key Points: 
  • ET today -
    CAMBRIDGE, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today reported second quarter 2023 financial and operating results.
  • Collaboration Revenues: Voyager had collaboration revenue of $4.9 million for the second quarter of 2023, compared to $0.7 million for the same period in 2022.
  • The increase was primarily due to revenue recognized during the second quarter of 2023 on the 2023 and 2019 strategic collaborations with Neurocrine Biosciences.
  • ET to discuss the second quarter 2023 financial and operating results.

Karuna Therapeutics Reports Second Quarter 2023 Financial Results and Provides General Business Updates

Retrieved on: 
Thursday, August 3, 2023
Research, Mental Health, Neurology, Clinical Trials, Health Insurance, Biotechnology, General Health, Pharmaceutical, Health, Science, Psychiatry, Psychosis, Schizophrenia, Clinical trial, NDA, ARISE, Clinical Global Impression, ASCP, ADEPT, Congress, Schizophrenia International Research Society, Annual general meeting, KRTX, KarXT, Therapy, Society, SIRS, Pharmaceutical industry

Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced financial results for the second quarter of 2023 and provided a general business update.

Key Points: 
  • Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced financial results for the second quarter of 2023 and provided a general business update.
  • Mr. Brown succeeds Troy Ignelzi who will remain at Karuna for a transition period through the end of the third quarter of 2023.
  • General and administrative expenses were $27.4 million for the second quarter of 2023, as compared to $17.8 million for the prior year period.
  • The second quarter 2023 financial results and business update will be discussed during a conference call and webcast today at 8:00 a.m.

Sustainable Growth in a Challenging World: AIIB's Eighth Annual Meeting Registration Opens

Retrieved on: 
Thursday, August 3, 2023
Press Conference (TV program), AIIB, Annual Meetings of the International Monetary Fund and the World Bank Group, Growth, Development, Business Roundtable, Conference, Asian Infrastructure Investment Bank, Annual general meeting, Tutoring, Management

BEIJING, Aug. 3, 2023 /PRNewswire/ -- More than 20 engaging sessions will explore trends and topics on sustainable growth at the 2023 Annual Meeting of the Board of Governors of the Asian Infrastructure Investment Bank (AIIB) .

Key Points: 
  • BEIJING, Aug. 3, 2023 /PRNewswire/ -- More than 20 engaging sessions will explore trends and topics on sustainable growth at the 2023 Annual Meeting of the Board of Governors of the Asian Infrastructure Investment Bank (AIIB) .
  • The 2023 AIIB Annual Meeting —with the theme "Sustainable Growth in a Challenging World"—consists of the Opening Ceremony, Governors' Business Roundtable, Governors' Official Session, Press Conference and a series of public and civil society engagement events.
  • The 2023 Annual Meeting will demonstrate AIIB's commitment to investment and action that drive growth toward a greener world as demonstrated by AIIB's mission of financing Infrastructure for Tomorrow.
  • Contact the AIIB Annual Meeting team if any registration questions: [email protected]
    Contact Lingxiao He for any media inquiries: [email protected]

Verona Pharma Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, August 3, 2023
Abstract, Maintenance, US Foods, D, SG, Information technology, Marketing, Conference call, Pharming, ATS, CMC, New Drug Application, NDA, Quality of life, EDT, AJRCCM, Chronic obstructive pulmonary disease, VRNA, American Journal, Data analysis, Patient, Risk, Annual general meeting, Research, FDA, Food, American Journal of Respiratory and Critical Care Medicine, Critical Care Medicine (journal), BST, Fine chemical, Pharmaceutical industry, Rare-earth element, Online shopping, COPD, Conference

LONDON and RALEIGH, N.C., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces its financial results for the second quarter ended June 30, 2023, and provides a corporate update.

Key Points: 
  • Conference call today at 9:00 a.m. EDT / 2:00 p.m. BST
    LONDON and RALEIGH, N.C., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces its financial results for the second quarter ended June 30, 2023, and provides a corporate update.
  • Net loss: Net loss was $8.8 million for the second quarter ended June 30, 2023 (Q2 2022: net loss $17.8 million).
  • Verona Pharma will host an investment community webcast and conference call at 9:00 a.m. EDT / 2:00 p.m. BST on Thursday, August 3, 2023, to discuss the second quarter 2023 financial results and the corporate update.
  • An electronic copy of the second quarter 2023 results press release will also be made available today on the Company’s website.